Opportunities for Biosimilars: A Multidisciplinary Perspective

Experts explore current and future use of biosimilars in dermatology, gastroenterology, and rheumatology.

Panelists explore opportunities for biosimilars to manage inflammatory conditions.

Clinical and social challenges associated with biosimilars are discussed by key opinion leaders.

Providers speak to the importance of being knowledgeable of efficacy and safety data before prescribing biosimilars to patients.

Experts compare approaches to prescribing biosimilars over reference drugs.

Panelists discuss reference biologic and biosimilar concentrations as well as the importance of citrate-free, less frequent injectable medications.

Vibeke Strand, MD, evaluates implementation of biosimilars in patients with no history of reference biologic use.

Insight surrounding the switch from reference drugs to biosimilars is provided by Bincy Abraham, MD, MS.

Medical experts discuss interchangeability designation requirements for biosimilars.

Professionals speak to auto-substitution and its Impact on the shared decision-making process associated with biosimilars.

Specialists define and discuss extrapolation, along with the importance of strong data in specific disease states.

Professionals explore the importance of indication-specific data in gastroenterology.

Key opinion leaders explore financial considerations associated with switching to biosimilar products.

Alice B. Gottlieb, MD, PhD, leads a discussion highlighting biosimilar utilization impact on payers and pharmacy benefit managers (PBMs).

Experts address the need for lower costs of treatment, as well as ways payers can support patients with the use of biologics.

Key topics for patient-provider conversations within the biosimilar landscape are highlighted by expert panelists.

Panelists provide final considerations surrounding biosimilar usage and considerations for optimal patient care.